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Factors associated with stroke or death after
carotid endarterectomy in Northern New England
Philip P. Goodney, MD, Donald S. Likosky, PhD, and Jack L. Cronenwett, MD, for the Vascular Study
Group of Northern New England, Lebanon, NH
Objective: This study investigated risk factors for stroke or death after carotid endarterectomy (CEA) among hospitals of
varying type and size participating in a regional quality improvement effort.
Methods:We reviewed 2714 patients undergoing 3092 primary CEAs (excluding combined procedures or redo CEA)
at 11 hospitals in Northern New England from January 2003 through December 2007. Hospitals varied in size (25
to 615 beds) and comprised community and teaching hospitals. Fifty surgeons reported results to the database.
Trained research personnel prospectively collected >70 demographic and clinical variables for each patient.
Multivariate logistic regression models were used to generate odds ratios (ORs) and prediction models for the
30-day postoperative stroke or death rate.
Results: Across 3092 CEAs, there were 38 minor strokes, 14 major strokes, and eight deaths (5 stroke-related) <30 days
of the index procedure (30-day stroke or death rate, 1.8%). In multivariate analyses, emergency CEA (OR, 7.0; 95%
confidence interval [CI], 1.8-26.9; P  .004), contralateral internal carotid artery occlusion (OR, 2.8; 95% CI, 1.3-6.2;
P .009), preoperative ipsilateral cortical stroke (OR, 2.4; 95% CI, 1.1-5.1; P .02), congestive heart failure (OR, 1.6;
95% CI, 1.1-2.4, P  .03), and age >70 (OR, 1.3; 95% CI, 0.8-2.3; P  .315) were associated with postoperative stroke
or death. Preoperative antiplatelet therapy was protective (OR, 0.4; 95% CI, 0.2-0.9; P  .02). Risk of stroke or death
varied from<1% in patients with no risk factors to nearly 5%with patients with>3 risk factors. Our risk predictionmodel
had excellent correlation with observed results (r  0.96) and reasonable discriminative ability (area under receiver
operating characteristic curve, 0.71). Risks varied from <1% in asymptomatic patients with no risk factors to nearly 4%
in patients with contralateral internal carotid artery occlusion (OR, 3.2; 95% CI, 1.3-8.1; P .01) and age>70 (OR, 2.9;
95% CI, 1.0-4.9, P  .05). Two hospitals performed significantly better than expected. These differences were not
attributable to surgeon or hospital volume.
Conclusion: Surgeons can “risk-stratify” preoperative patients by considering the variables (emergency procedure,
contralateral internal carotid artery occlusion, preoperative ipsilateral cortical stroke, congestive heart failure, and age),
reducing risk with antiplatelet agents, and informing patients more precisely about their risk of stroke or death after CEA.
Risk prediction models can also be used to compare risk-adjusted outcomes between centers, identify best practices, and
hopefully, improve overall results. ( J Vasc Surg 2008;48:1139-45.)Several groups have reported risk factors associated
with stroke or death after carotid endarterectomy
(CEA), with the intent of improving preoperative assess-
ment and patient selection.1-6 Across these studies, the
most consistent risk factor found to predict stroke or
death after CEA has been preoperative neurologic symp-
toms (Table I).1-3,5-8 Other variables associated with
increased operative risk have included emergency oper-
ation,1 renal failure,5 and diabetes.3 Interestingly, pre-
operative antiplatelet medications were found to be pro-
tective in only one of these models,6 despite level 1
evidence that such therapy reduces stroke risk associated
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studies used administrative data, without access to clinic-
level data such as use of antiplatelet agents.3
Another role for risk prediction models is to allow
comparison of risk-adjusted outcomes among different
centers. An important element in surgical quality improve-
ment is to establish benchmarks for performance.13-15
Benchmarks allow surgeons and hospitals to measure their
performance relative to others, which can lead to adoption
of best practices.16 Most outcome benchmarks require risk
adjustment, to account for potential differences in patient
populations that could influence outcomes.17 Accordingly,
multivariate risk prediction models are developed to ac-
count for differences in patient characteristics when out-
comes are compared.18,19
We have developed a regional quality improvement
program in vascular surgery involving 50 surgeons in 11
centers in our region. This group has prospectively col-
lected both detailed patient demographic, operative, and
clinical outcome data for CEA since 2003.20 We hypothe-
sized that a clinic-level database such as this might disclose
new patient-level characteristics that were associated with
stroke or death after CEA based on contemporary practice
in a variety of hospital types.
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Subjects and databases. This report uses data col-
lected as part of the Vascular Study Group of Northern
New England (VSGNNE), a regional cooperative quality
improvement initiative developed in 2002 to study regional
outcomes in vascular surgery. Further details on this data-
base have been published previously.20
For this analysis, we included only patients who under-
went primary CEA (excluding redo operations or those
combined with coronary bypass grafting). The analysis
included all patients who underwent CEA by participating
surgeons in the 11 study hospitals from January 1, 2003,
through December 31, 2007. Trained nurses or clinical
data abstractors entered data prospectively on 70 clinical
and demographic variables. Research analysts were blinded
to patient, surgeon, and hospital identity.
The VSGNNE data were validated using discharge
claims data from each participating institution. These audits
aimed to ensure not only complete inclusion of all CEAs
performed in study hospitals but also to confirm our main
outcome measure, 30-day postoperative stroke or death.
Specifically, we evaluated International Classification of
Diseases, 9th Revision (ICD9) codes for CEA (38.12),
postoperative iatrogenic stroke (997.02), and discharge
status (alive, dead).
The validation analyses found initially that 92% of
CEAs that had been performed by participating surgeons
during the specified time interval at all centers had been
entered into the VSGNNE database. Data from the re-
maining 8% of patients were then retrieved from hospital
charts. Thus, this data set represents 100% of CEAs per-
formed by VSGNNE members during the specified time
period. An audit of cases with administrative codes for
postoperative iatrogenic stroke revealed that these patients
were properly recorded in VSGNNE. In addition, three
strokes were reported to VSGNNE that had not been
coded in claims data. No postoperative strokes captured in
claims data had been “missed” by the VSGNNE data-
reporting mechanism.
We obtained discharge follow-up status for 100% of
Table I. Previous studies analyzing risk of stroke or death
First author (year) Patients, No. Study typ
Musser (1994)1 562 Single-center, retrospec
Goldstein (1998)7 1160 Multicenter, retrospecti
database
Rothwell (1999)2 2060 Multicenter, prospective
Plaque characteristics
Frawley (2000)8 1000 Single-center retrospect
Kresowik (2001)6 10,561 Retrospective chart revi
beneficiaries
Tu (2003)3 6038 Regional retrospective d
Nicolaides (2005)5 1115 Prospective clinical trial
AF, Arial fibrillation; CHF, congestive heart failure; DM, diabetes mellitu
ventricular contractions.patients and 30-day follow-up status for 89% of patients.The 11% of patients for whom long-term follow-up was not
available underwent discharge abstract and Social Security
Death Index audit. This audit was performed to ensure that
no deaths had been reported using claims data but had not
been reported to the VSG. This audit failed to reveal any
additional deaths that were not reported in the VSG data-
base.
Outcome and variable definitions. We selected 30-
day postoperative stroke or death as our main outcome
measure. Major stroke was defined as disability causing
non-independent living status; minor stroke was defined as
nondisabling. The determination of major or minor stroke
was made according to these definitions by the nurse clini-
cian or trained research assistant responsible for entering
the data into the database at each participating institution.
Operative volume categories were defined using cut points
guided by prior studies,21-23 modified to create tertiles of
approximately equal size from our data set. Our volume
analyses were repeated with quartiles and quintiles, and at
several different volume cut points, without any changes in
findings.
Preoperative medication usage was defined as adminis-
tration 36 hours before surgery, confirmed by examina-
tion of the patient record by the surgeon or research
personnel reporting the data. Urgent surgery was defined as
surgery required 24 hours of admission, and emergency
surgery was defined as surgery required6 hours of admis-
sion. Symptomatic status was subdivided by symptom type:
ocular (visual loss or blurring), cortical (transient ischemic
attack [TIA], stroke), vertebrobasilar (ataxia, bilateral mo-
tor deficits), and miscellaneous (global or other symp-
toms).
Risk model construction. To predict 30-day postop-
erative stroke or death, we initially performed univariate
comparisons between our main outcome measures and
many patient-level variables. We selected appropriate pa-
tient preoperative variables for comparison based on previ-
ous publications.1,3,24-26 Although our major interest in
developing this model was to examine preoperative patient
risk, we also examined the effect of intraoperative factors
carotid endarterectomy
Risk factors
ries AF, emergency operation, PVCs, intra-op
hypotension, ESRD
ministrative Female, age 75, CHF
 Symptomatic status, DM, recent MI
ries Female gender
 Medicare Aspirin/ticlopidine use, heparin use, patch
angioplasty
se Symptomatic status, AF, contralateral occlusion,
CHF, DM
Symptomatic status, degree of stenosis, creatinine
RD, end-stage renal disease; MI, myocardial infarction; PVC, prematureafter
e
tive se
ve ad
 trial
ive se
ew of
ataba
 such as shunt or patch usage because our goal was to
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ables tested in univariate analysis are reported in Table II.
Univariate patient-level predictors that were significant at
P  .10 were then entered into a multivariate model using
backwards stepwise multivariate logistic regression, which
was used to generate odds ratios (ORs) and 95% confidence
intervals (CIs) for 30-day postoperative stroke or death.
The Institutional Review Board at Dartmouth Medical
School reviewed and approved our study protocol.
We used the resulting model to calculate an expected
stroke/death rate for each patient, based on that particular
Table II. Univariate analysis of 30-day stroke or death
Variable
Stroke/death
rate, %
P
If not
present
If
present
Patient characteristics
Urgent operation 1.7 3.5 .022a
Emergency operation 1.7 13.0 .0001a
Age 70 1.6 2.0 .378
Age 80 1.8 1.6 .799
Female sex 2.1 1.4 .161
Smoking (prior or current) 1.7 1.8 .989
Diabetes 1.8 1.7 .914
Hypertension 1.4 1.9 .772
-Blockers 1.8 1.8 .955
Coronary disease 1.7 1.9 .87
Congestive heart failure 1.6 3.5 .045a
Degree of stenosis
Ipsilateral 60% 1.7 5.7 .029a
Ipsilateral 70% 1.8 1.5 .789
Ipsilateral 80% 1.8 1.4 .44
Ipsilateral 90% 1.6 1.8 .713
Contralateral ICA occlusion 1.6 4.0 .014a
Symptom status
Ipsilateral symptoms 1.4 2.8 .014a
Cortical
TIA 1.7 2.2 .395
Stroke 1.6 3.5 .007a
Ocular 1.7 1.3 .885
Vertebrobasilar 1.7 1.4 .975
Contralateral symptoms (all) 1.7 1.6 .775
Pre-op medication regimen
Anti-platelet agent
ASA only 3.1 1.5 .013a
Clopidogrel only 1.9 1.0 .141
ASA  clopidogrel 3.3 1.5 .04a
Statin use 2.3 1.5 .146
-Blocker use 1.4 1.7 .526
Operative characteristics
General anesthesia 0.8 1.8 .268
Routine shunting 1.8 1.6 .671
Shunting for neurologic changes
only 1.6 3.2 .088
Eversion endarterectomy 1.7 2.2 .434
Patch angioplasty 2.4 1.5 .096
Dextran use 1.7 2.8 .274
Intravenous antihypertensive use 1.7 2.5 .573
Completion study 1.2 2.6 .014a
ASA, acetylsalicylic acid; TIA, transient ischemic attack.
aStatistically significant (P  .05).patient’s characteristics. By this method, we were able torisk-adjust outcomes for each hospital by calculating ob-
served (O) to expected (E) stroke or death rates for the
patients treated at that hospital. Although 11 participating
hospitals contributed CEA data to the registry, we elimi-
nated any center that did not perform at least 50 CEAs
during the study period when comparing centers, leaving
eight centers available for comparison of O/E outcomes at
the “center” level. Kruskal-Wallis comparisons determined
significance between O/E rates across centers. All analyses
were performed using Excel (Microsoft Corp, Redmond,
Wash) and Stata software (StataCorp, College Station,
Texas). All tests of significance were performed at the 0.05
level.
RESULTS
Overall, we studied 2714 patients undergoing 3092
primary CEAs. Most patients were men, with a history of
smoking and hypertension, and nearly half were symptom-
atic (Table III). Most procedures were performed elec-
tively, under general anesthesia. Eversion endarterectomy
was seldom used, and shunts and patches were commonly
used.
Across these 3092 CEAs, we found 38 minor strokes,
14 major strokes, and eight deaths (5 stroke related) 30
days of the index procedure, for a 30-day stroke/death rate
of 1.8%). Five of the 52 strokes (10%) and two of the eight
Table III. Patient and operative characteristics
Characteristic Value
Total carotid endarterectomies, No. 3092
Average age, years 69
Male 59%
Smoker (current or prior) 79%
History of hypertension 86%
History of diabetes 30%
History of coronary disease 35%
Pre-op -blocker use 82%
Pre-op antiplatelet agent use 86%
Pre-op statin use 67%
Symptomatic carotid disease (any symptom)a 44%
Ocular symptoms, ipsilateral 16%
Ocular symptoms, contralateral 2.5%
Cortical symptoms, ipsilateral
Transient ischemic attack 22%
Stroke 11%
Cortical symptoms, contralateral
Transient ischemic attack 1.2%
Stroke 1.7%
Vertebrobasilar symptoms
Transient ischemic attack 2.3%
Stroke 0.2%
Nonspecific symptoms 5.6%
Operative details
Urgent/emergency procedure 10%
General anesthesia 92%
Eversion endarterectomy 15%
Shunt 46%
Patch angioplasty 76%
aNot additive across symptom categories, as some patients had more than
one category of symptoms.deaths (25%) were reported after discharge but 30 days.
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are reported in Table II. Emergency operation, contralat-
eral internal carotid artery (ICA) occlusion, ipsilateral cor-
tical symptoms (both TIA and stroke), congestive heart
failure, performance of a completion study, and ICA steno-
sis60% all were associated with an increased risk of 30-day
stroke or death. Of the patients with ICA stenosis 60%,
36 of 53 (68%) were symptomatic.
Preoperative use of antiplatelet medications decreased
the risk of 30-day stroke or death by nearly 50% in univar-
iate analysis. Operative variables such as shunt use, arteri-
otomy closure method, dextran infusion, and use of intra-
venous antihypertensive drugs after surgery were not
predictive of stroke or death at 30 days.
By multivariate analysis, emergency procedure, con-
tralateral ICA occlusion, preoperative ipsilateral cortical
stroke, congestive heart failure, and age 70 years were
associated with a significantly higher risk of stroke or death,
whereas preoperative acetylsalicylic acid (ASA) or clopi-
dogrel use was protective (Table IV). We examined the
impact and additive effects of the number of risk factors
present (Fig 1). In patients with none to one of these risk
factors, the risk of stroke or death was1%; however, when
Table IV. Multivariate analysis of factors associated with
30-day stroke or death after carotid endarterectomya
Variable OR 95% CI P
Age 70 years 1.3 0.8-2.3 0.315
Contralateral ICA occlusion 2.8 1.3-6.2 0.009
Antiplatelet agent use 0.4 0.2-0.9 0.02
Congestive heart failure 1.6 1.1-2.4 0.03
Emergency procedureb 7.0 1.8-26.9 0.004
Pre-op ipsilateral cortical symptoms 2.4 1.1-5.1 0.02
CI, Confidence interval; ICA, internal carotid artery; OR, odds ratio.
aArea under receiver operating characteristic curve, 0.71.
bA procedure 6 hours of admission.
Fig 1. Comparison of observed (gray bars) and expected (black
bars) 30-day stroke/death rate. Risk factors include emergency
procedure, preoperative ipsilateral stroke, age 70, lack of anti-
platelet agent, contralateral internal carotid artery occlusion, and
congestive heart failure.patients had three or more risk factors, the risk of stroke ordeath increased to nearly 5%. When expected stroke or death
rates were compared with the observed stroke or death
rates, excellent correlation was observed (r  0.96). The
model was found to have reasonable discriminative ability
(area under receiver operating characteristic [AUROC]
curve, 0.71).
We repeated our analysis in the subgroup of asymptom-
atic patients. Multivariate analysis showed that contralateral
ICA occlusion (OR, 3.7; 95% CI, 1.5-9.4; P  .006) and
age 70 years (OR, 2.9; 95% CI, 1.0-4.9; P  .05) were
associated with an increased risk of 30-day stroke or death.
The predicted patient risk of stroke or death in asymptom-
atic patients varied from1% in patients with no risk factors
to nearly 4% in patients aged70 years with a contralateral
ICA occlusion (Fig 2). This model also had reasonable
discriminative ability (AUROC curve, 0.69), but very few
patients (88 of 1973) were within the highest risk category,
limiting the generalizability of these findings in higher-risk
asymptomatic patients.
To benchmark performance across hospitals, we calcu-
lated expected 30-day stroke/death rates for each patient
using our prediction model and compared observed and
expected stroke/death rates by hospital (Table V). Across
eight hospitals, the expected stroke/death rate ranged from
1.5% to 2.0%, whereas observed results varied from 0% to
4%. Two hospitals had O/E ratios 1, indicating a
higher observed 30-day stroke/death rate than expected.
The remaining six hospitals all had O/E ratios of 1,
indicating lower 30-day stroke/death rates than expected;
in two of these hospitals, these differences were statistically
significant.
Differences across hospitals were not attributable to
differences in hospital or surgeon volume (Fig 3). In fact,
the hospital with the highest volume in our analysis (975
CEAs performed by 10 surgeons) had the highest 30-day
Fig 2. Comparison of observed (gray bars) and expected (black
bars) 30-day stroke/death rate, in asymptomatic patients. Risk
factors include age 70 and contralateral internal carotid artery
occlusion.stroke/death rate, and a hospital with relatively small vol-
ected
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deaths during the study period.
DISCUSSION
In contrast with previous models for predicting stroke
Table V. Comparison of observed and expected 30-day st
Variable Overall 1 2
CEAs, No. 3092 162 975 2
Risk of stroke/death
Expected 1.8% 2.0% 2.0%
Observed 1.8% 4.3% 3.0%
O/E ratiob 2.1 1.5
P (observed vs expected) .132 .06
CEA, Carotid endarterectomy.
aOnly hospitals performing at least 50 CEAs during the study period were i
eliminated from this portion of the analysis.
bRatio of observed-to-expected 30-day stroke/death rates. A number 1 i
lower stroke/death rate than expected.
cIndicate observed stroke/death rates significantly higher or lower than exp
Fig 3. Thirty-day stroke/death rate by (A) annual hospital vol-
ume of carotid endarterectomies (CEA; P  .143 across volume
categories) and (B) annual surgeon volume (P  .642 across
volume categories).or death after CEA, our model was derived from a prospec-tive collection of contemporary data derived from 50 sur-
geons in 11 hospitals that varied in size from 25 to 615 beds
and comprised both academic and community centers. We
identified emergency procedure, contralateral ICA occlu-
sion, preoperative cortical stroke, congestive heart failure,
increased age, and lack of antiplatelet agent use as predic-
tive of postoperative 30-day stroke or death after CEA.
Our model describes several risk factors reported in
previous studies (Table I), with similar effect sizes. Two
prior models reported an OR of 1.8 for 30-day stroke or
death for contralateral ICA occlusion, which is similar in
magnitude to our OR of 2.8.2,3 These same studies2,3 also
reported that ipsilateral cerebral symptoms increased the
risk of stroke and death nearly twofold, similar to our
finding of an OR of 2.4 for preoperative ipsilateral stroke.
We did not find that preoperative cortical TIA or ocular
symptoms were significantly predictive of stroke or death;
only preoperative ipsilateral stroke predicted 30-day post-
operative stroke or death. Although we suspect that this
represents a type II error, this finding may also reflect the
increased impact of previous stroke, compared with TIAs.
Patients with preoperative stroke before CEA have been
shown to be at higher risk for postoperative stroke, inde-
pendent of whether or not they have TIAs at the time of
CEA.27 Lastly, emergency CEA, usually indicated for free-
floating thrombus or crescendo symptoms, has been well
described as having worse surgical outcomes compared
with routine or urgent CEA,28 in keeping with our find-
ings. Common risk factors with similar effect sizes to pre-
vious studies lend credence to the generalizability of our
model.
Our finding of a protective effect of preoperative ASA
or clopidogrel is not surprising given previous research.
The benefit of ASA to reduce postoperative stroke or death
was first shown in a secondary analysis from the North
American Symptomatic Carotid Endarterectomy Trial29 in
1991. Subsequently, a small, randomized trial showed that
stroke rates were reduced with lower-dose perioperative
ASA (81 mg/d) vs placebo.9 The ASA and Carotid Endar-
terectomy (ACE) trial12 further emphasized the benefit of
/death rates by hospitala
Hospital
4 5 6 7 8
385 329 90 285 561
% 1.8% 1.5% 1.6% 1.5% 1.6%
% 1.3% 0.9% 0.0% 1.1% 0.5%
3 0.73 0.60 0.0c 0.67 0.32c
16 .412 .252 .001c .415 .002c
d in this analysis; therefore, 3 centers representing a total of 61 CEAs were
es a higher stroke/death rate than expected, and a number 1 indicates a
.roke
3
44
1.9
1.2
0.6
.3
nclude
ndicatlow-dose ASA by randomizing 2849 patients to escalating
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stroke, death, or myocardial infarction was lowest in the
lower-dose (81 and 325 mg) groups than with higher
doses. Finally, Kresowik et al6 noted a 30% reduction in
stroke or death with the use of preoperative antiplatelet
therapy in review of 10,000 Medicare beneficiaries un-
dergoing CEA between 1995 and 1996. Other antiplatelet
agents have not been as extensively studied in terms of their
benefit for stroke reduction after CEA, but recent studies of
clopidogrel provide evidence that perioperative emboliza-
tion is reduced.10,11 Given this body of evidence, it is not
surprising that our risk prediction model, based on clinic-
level detail, noted a protective effect from antiplatelet
therapy.
Clearly, perioperative antiplatelet medication use is
simple method to substantially reduce stroke and death
after CEA, and many consider its administration “routine.”
However, a recent study from the Netherlands indicated
that only 66% of patients undergoing CEA were receiving
preoperative antiplatelet agents, showing the opportunity
for improvement using this simple process.30 Even within
our region, before starting our quality improvement ef-
forts, only 73% of patients undergoing CEA were taking
antiplatelet agents. However, this percentage has increased
to 93% after dedicated efforts to improve this process
measure across our participating centers.31
After risk adjustment for underlying patient character-
istics, we found residual differences in outcome across
hospitals, which are likely due to differences in processes of
care. Our analysis did not disclose any significant influence
of operative variables such as shunt use, arteriotomy closure
method, dextran infusion, or use of intravenous antihyper-
tensives after surgery. Our plan is to use benchmarking site
visits to identify processes of care that differ across surgeons
and hospitals, with the hope of identifying “best practices”
in CEA. After identifying the processes of care that produce
the best results, we hope to implement these processes to
improve care across all centers, a technique that has been
successfully used by cardiac surgeons in our region.32
Although our study found that outcome was not influ-
enced by surgeon or hospital volume, this is likely a type II
error given prior publications on this topic.21-23 Most
studies that found a surgeon volume effect for CEA out-
come required hundreds of surgeons and tens of thousands
of patients to find a relatively small effect,21,22 whereas we
studied only 50 surgeons performing 3000 CEAs. None-
theless, our analysis found no dramatic influence on out-
come differences between centers in our region according
to volume.
Our subgroup analysis of asymptomatic patients found
two important predictors of stroke or death after CEA:
contralateral ICA occlusion and age 70. Stroke or death
rates were acceptable in patients with only one (or none) of
these risk factors, but patients with both contralateral ICA
occlusion and age 70 had a predicted stroke risk of 4%.
Although conclusions are limited by the small number of
patients meeting these criteria in our population, these data
warrant further investigation, because a stroke or death rateof 4% in asymptomatic patients is outside the clinical guide-
lines for performing CEA.33 If confirmed in larger analyses,
these data would indicate the need for better patient selec-
tion in the treatment of asymptomatic carotid stenosis.
Our study has several limitations. First, our relatively
low event rate may have resulted in a type II error, limiting
our ability to identify other predictors of outcome after
CEA, such as a benefit for statins, as has been shown in
other series.34-36 However, the significant risk factors that
we identified agree with previous reports and are likely
valid.
Second, 30-day follow-up was missing in our database
in 11% of patients. We used the Social Security Death Index
to ensure that there were no unreported deaths in this
group. We estimate that we may have missed one to two
strokes in this period, based on our analysis of patients with
complete follow-up, in which only 10% of postoperative
strokes occurred after discharge but 30 days. This could
have increased our postoperative stroke/death rate from
1.8% to 2.0 to 2.2%, but should not have affected our risk
adjustment calculations.
CONCLUSIONS
We identified factors associated with 30-day stroke or
death after CEA by using our regional prospective data-
base. Surgeons can easily preoperatively “risk-stratify”
patients by considering these easily available variables—
emergency nature of the procedure, contralateral ICA oc-
clusion, preoperative ipsilateral cortical stroke, congestive
heart failure, and age—which may aid decision making for
patients who are at the borderline for benefit from CEA. In
addition, by using perioperative antiplatelet agents, sur-
geons can impart measurable risk reduction. Finally, risk
adjustment models like this allow valuable benchmarking
among different centers.
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